Japan Chemical Daily

Japan's leading chemical industry newspaper

Log In

AGC Plans to Invest Over 200B Yen in CDMO Operations for Gene & Cell Therapy, More

Filed Under: Pharma Tagged With: , , , , ,

AGC Inc. (TYO:5201) is looking to invest more than 200 billion yen ($1.7 billion) into CDMO operations by 2025. Plans…...

Please subscribe to read the full story.

Subscribe Free Trial

Related Articles:

AGC Looks to Advance Into Gene and Cell Therapy Business With Tender Offer for MolMed
AGC Looks to Advance Into Gene and Cell Therapy Business…
AGC in Race to Bolster CDMO Operations Across US, Europe and Japan
AGC in Race to Bolster CDMO Operations Across US, Europe and…
Japanese Chemical Companies Find Special Demand for Bio-CDMO Operations Amid COVID-19
Japanese Chemical Companies Find Special Demand for Bio-CDMO…
Asahi Kasei Targets Sales of 1 Trillion Yen in Health Care Sector
Asahi Kasei Targets Sales of 1 Trillion Yen in Health Care…
Sekisui Chemical to Build New Biopharmaceutical Plant in UK
Sekisui Chemical to Build New Biopharmaceutical Plant in UK
Chitose Bio Evolution Moves Forward on Chemical, Bio-CDMO Mass Production in Japan
Chitose Bio Evolution Moves Forward on Chemical, Bio-CDMO…